UPDATE: Morgan Stanley Reiterates On Albany Molecular Research Ahead Of Conference Call

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on Albany Molecular Research AMRI, but removed the $21.00 price target. In the report, Morgan Stanley noted, “We are hosting AMRI's CEO Bill Marth and CFO Mike Nolan today, June 16th at 2pm ET as part of our CEO/CFO conference call series. On the call we will discuss key investor questions, highlighted below.” Albany Molecular Research closed on Friday at $18.58.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsMorgan StanleyRicky R. Goldwasser
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!